Literature DB >> 19762714

Role of MKP-1 in osteoclasts and bone homeostasis.

Jodi Carlson1, Weiguo Cui, Qing Zhang, Xiaoqing Xu, Fatih Mercan, Anton M Bennett, Agnès Vignery.   

Abstract

Bone mass is maintained through the complementary activities of osteoblasts and osteoclasts; yet differentiation of either osteoblasts and osteoclasts engages the mitogen-activated protein kinase (MAPK) pathway. The MAPKs are negatively regulated by a family of dual-specificity phosphatases known as the MAPK phosphatases (MKPs). MKP-1 is a stress-responsive MKP that inactivates the MAPKs and plays a central role in macrophages; however, whether MKP-1 plays a role in the maintenance of bone mass has yet to be investigated. We show here, using a genetic approach, that mkp-1(-/-) female mice exhibited slightly reduced bone mass. We found that mkp-1(+/+) and mkp-1(-/-) mice had equivalent levels of bone loss after ovariectomy despite mkp-1(-/-) mice having fewer osteoclasts, suggesting that mkp-1(-/-) osteoclasts are hyperactive. Indeed, deletion of MKP1 led to a profound activation of osteoclasts in vivo in response to local lipopolysaccharide (LPS) injection. These results suggest a role for MKP-1 in osteoclasts, which originate from the fusion of macrophages. In support of these observations, receptor activator for nuclear factor-kappaB ligand induced the expression for MKP-1, and osteoclasts derived from mkp-1(-/-) mice had increased resorptive activity. Finally, receptor activator of nuclear factor-kappaB ligand-induced p38 MAPK and c-Jun NH2-terminal kinase activities were enhanced in osteoclasts derived from mkp-1(-/-) mice. Taken together, these results show that MKP-1 plays a role in the maintenance of bone mass and does so by negatively regulating MAPK-dependent osteoclast signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762714      PMCID: PMC2751553          DOI: 10.2353/ajpath.2009.090035

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

2.  Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL).

Authors:  M Matsumoto; T Sudo; T Saito; H Osada; M Tsujimoto
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

3.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

Authors:  J Li; I Sarosi; X Q Yan; S Morony; C Capparelli; H L Tan; S McCabe; R Elliott; S Scully; G Van; S Kaufman; S C Juan; Y Sun; J Tarpley; L Martin; K Christensen; J McCabe; P Kostenuik; H Hsu; F Fletcher; C R Dunstan; D L Lacey; W J Boyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 4.  The osteoblast: a sophisticated fibroblast under central surveillance.

Authors:  P Ducy; T Schinke; G Karsenty
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

5.  Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation.

Authors:  S Srivastava; G Toraldo; M N Weitzmann; S Cenci; F P Ross; R Pacifici
Journal:  J Biol Chem       Date:  2000-12-19       Impact factor: 5.157

Review 6.  Mechanisms balancing skeletal matrix synthesis and degradation.

Authors:  Harry C Blair; Mone Zaidi; Paul H Schlesinger
Journal:  Biochem J       Date:  2002-06-01       Impact factor: 3.857

7.  Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts.

Authors:  K Dorfman; D Carrasco; M Gruda; C Ryan; S A Lira; R Bravo
Journal:  Oncogene       Date:  1996-09-05       Impact factor: 9.867

8.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

Review 9.  Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts.

Authors:  Zang Hee Lee; Hong Hee Kim
Journal:  Biochem Biophys Res Commun       Date:  2003-05-30       Impact factor: 3.575

Review 10.  Corticosteroid receptors, macrophages and cardiovascular disease.

Authors:  Amanda J Rickard; Morag J Young
Journal:  J Mol Endocrinol       Date:  2009-01-21       Impact factor: 5.098

View more
  22 in total

1.  Keep the 'phospho' on MAPK, be happy.

Authors:  Schahram Akbarian; Roger J Davis
Journal:  Nat Med       Date:  2010-11       Impact factor: 53.440

2.  Immune and inflammatory pathways are involved in inherent bone marrow ossification.

Authors:  Umut Atakan Gurkan; Ryan Golden; Vipuil Kishore; Catherine P Riley; Jiri Adamec; Ozan Akkus
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

Review 3.  Mitogen-activated protein kinase phosphatase-1 - a potential therapeutic target in metabolic disease.

Authors:  Rachel J Roth Flach; Anton M Bennett
Journal:  Expert Opin Ther Targets       Date:  2010-12       Impact factor: 6.902

4.  Mitogen-activated protein kinase phosphatase-1 is a key regulator of hypoxia-induced vascular endothelial growth factor expression and vessel density in lung.

Authors:  Kristin M Shields; Evgeniy Panzhinskiy; Nana Burns; W Michael Zawada; Mita Das
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

5.  MKP-1 is essential for canonical vitamin D-induced signaling through nuclear import and regulates RANKL expression and function.

Authors:  Alfred C Griffin; Michael J Kern; Keith L Kirkwood
Journal:  Mol Endocrinol       Date:  2012-08-16

6.  Mitogen-activated protein kinase phosphatase 1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone.

Authors:  Chandrika D Mahalingam; Tanuka Datta; Rashmi V Patil; Jaclynn Kreider; R Daniel Bonfil; Keith L Kirkwood; Steven A Goldstein; Abdul B Abou-Samra; Nabanita S Datta
Journal:  J Endocrinol       Date:  2011-08-18       Impact factor: 4.286

7.  Identification of NURR1 as a mediator of MIF signaling during chronic arthritis: effects on glucocorticoid-induced MKP1.

Authors:  Jennifer A Ralph; Afsar U Ahmed; Leilani L Santos; Andrew R Clark; Jason McMorrow; Evelyn P Murphy; Eric F Morand
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

8.  Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss.

Authors:  H Yu; Q Li; B Herbert; R Zinna; K Martin; C R Junior; K L Kirkwood
Journal:  Gene Ther       Date:  2010-11-11       Impact factor: 5.250

9.  NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis.

Authors:  Claudia Goettsch; Andrea Babelova; Olivia Trummer; Reinhold G Erben; Martina Rauner; Stefan Rammelt; Norbert Weissmann; Valeska Weinberger; Sebastian Benkhoff; Marian Kampschulte; Barbara Obermayer-Pietsch; Lorenz C Hofbauer; Ralf P Brandes; Katrin Schröder
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

10.  MKP-1 signaling events are required for early osteoclastogenesis in lineage defined progenitor populations by disrupting RANKL-induced NFATc1 nuclear translocation.

Authors:  Michael S Valerio; Bethany A Herbert; Alfred C Griffin; Zhuang Wan; Elizabeth G Hill; Keith L Kirkwood
Journal:  Bone       Date:  2013-11-20       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.